决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:The Spatial Context of Tumor-Infiltrating Immune Cells Associates with Improved Ovarian Cancer Survival.
The Spatial Context of Tumor-Infiltrating Immune Cells Associates with Improved Ovarian Cancer Survival.
我们对HGSOC组织芯片(n = 127)进行了多重IHC,以表征肿瘤内的免疫细胞组成。
卵巢癌是致死率最高的妇科恶性肿瘤。多组学技术为改进治疗反应和患者预后的预测建模提供了平台。虽然高级别浆液性癌(HGSOC)肿瘤具有免疫原性,且大量研究已证实其与免疫细胞浸润呈正相关,但临床试验中的免疫疗法有效率较低。目前亟需更好地理解免疫细胞在介导卵巢癌治疗反应和疾病进展中的作用及组成。我们对HGSOC组织芯片(n = 127)进行了多重IHC染色,以表征肿瘤内免疫细胞的组成。在分析肿瘤内T细胞(CD4/CD8)、巨噬细胞(CD68)和B细胞(CD19)的组成及空间分布后,我们发现B细胞和CD4 T细胞数量增加与总生存期相关。更重要的是,我们观察到肿瘤相关巨噬细胞与B细胞或CD4 T细胞之间的邻近程度与总生存期显著相关。意义:这些结果突出了B细胞和CD4 T细胞的抗肿瘤作用,并且免疫细胞类型之间的空间相互作用是治疗反应和患者预后的新型预测指标。
Ovarian cancer is the deadliest gynecologic malignancy. Multi-omics techniques have provided a platform for improved predictive modeling of therapy response and patient outcomes. While high-grade serous carcinoma (HGSOC) tumors are immunogenic and numerous studies have defined positive correlation to immune cell infiltration, immunotherapies in clinical trials have exhibited low efficacy rates. There is a significant need to better comprehend the role and composition of immune cells in mediating ovarian cancer therapeutic response and progression. We performed multiplex IHC with an HGSOC tissue microarray ( n = 127) to characterize the immune cell composition within tumors. After analyzing the composition and spatial context of T cells (CD4/CD8), macrophages (CD68), and B cells (CD19) within the tumor, we found that increased B-cell and CD4 T-cell presence correlated with overall survival. More importantly, we observed that the proximity between tumor-associated macrophages and B cells or CD4 T cells significantly correlated with overall survival. IMPLICATIONS: The results highlight the antitumor role of B cells and CD4 T cells, and that the spatial interactions between immune cell types are a novel predictor of therapeutic response and patient outcomes.
MEMBER ACCOUNT
登录成功会直接打开下一页。